Insmed Incorporated (INSM)

Market Cap	3.93B
Revenue (ttm)	280.82M
Net Income (ttm)	-723.63M
Shares Out	143.06M
EPS (ttm)	-5.29
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,981,369
Open	26.68
Previous Close	26.97
Day's Range	26.62 - 27.72
52-Week Range	16.04 - 27.72
Beta	1.33
Analysts	Strong Buy
Price Target	42.00 (+52.84%)
Earnings Date	Oct 26, 2023

About INSM

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis, cystic fibrosis, and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled f...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 1, 2000
• Employees: 736
• Stock Exchange: NASDAQ
• Ticker Symbol: INSM

Financial Performance

In 2022, Insmed's revenue was $245.36 million, an increase of 30.19% compared to the previous year's $188.46 million. Losses were -$481.53 million, 10.8% more than in 2021.

Analyst Forecast

According to 11 analysts, the average rating for INSM stock is "Strong Buy." The 12-month stock price forecast is $42.0, which is an increase of 52.84% from the latest price.

Price Target

$42.0

(52.84% upside)

Analyst Consensus: Strong Buy